Selenoprotein W engages in overactive osteoclast differentiation in multiple myeloma
Molecular Biology Reports · 2024
DOI: 10.1007/s11033-024-09517-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Biology Reports, 2024. Verfasst von Hyunsoo Kim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Bone Metabolism and Control, Department of Microbiology, Yeungnam University College of Medicine, Daegu, 42415, Korea. Hauptthemen laut MEDLINE: Cell Differentiation, Multiple Myeloma, Osteoclasts, Selenoprotein W. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Background
Patients with multiple myeloma exhibit malignant osteolytic bone disease due to excessive osteoclast formation and function. We recently identified that osteoclastogenic stimulator selenoprotein W (SELENOW) is upregulated via ERK signaling and downregulated via p38 signaling during receptor activator of nuclear factor (NF)-κΒ ligand (RANKL)-induced osteoclast differentiation. In the intrinsic physiological process, RANKL-induced downregulation of SELENOW maintains proper osteoclast differentiation; in contrast, forced overexpression of SELENOW leads to overactive osteoclast formation and function. Methods and results We observed that SELENOW is highly expressed in multiple myeloma-derived peripheral blood mononuclear cells (PBMCs) and mature osteoclasts when compared to healthy controls. Also, the level of tumor necrosis factor alpha (TNFα), a pathological osteoclastogenic factor, is increased in the PBMCs and serum of patients with multiple myeloma. ERK activation by TNFα was more marked and sustained than that by RANKL, allowing SELENOW upregulation. Excessive expression of SELENOW in osteoclast progenitors and mature osteoclasts derived from multiple myeloma facilitated efficient nuclear translocation of osteoclastogenic transcription factors NF-κB and NFATc1, which are favorable for osteoclast formation.
Conclusion
Our findings suggest a possibility that feedforward signaling of osteoclastogenic SELENOW by TNFα derived from multiple myeloma induces overactive osteoclast differentiation, leading to bone loss during multiple myeloma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Bone Metabolism and Control, Department of Microbiology, Yeungnam University College of Medicine, Daegu, 42415, Korea.
- Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA19104, USA.
- Department of Hematology-Oncology, Yeungnam University College of Medicine, Daegu, 42415, Korea.
- Laboratory of Bone Metabolism and Control, Department of Microbiology, Yeungnam University College of Medicine, Daegu, 42415, Korea. dwjeong@ynu.ac.kr.
- Company of The Bone Science, Yeungnam University College of Medicine, Daegu, 42415, Korea. dwjeong@ynu.ac.kr.
Förderung
- National Research Foundation of Korea
Zitieren
APA
Kim, H., Oh, J., Kim, M. K., Lee, K. H., & Jeong, D. (2024). Selenoprotein W engages in overactive osteoclast differentiation in multiple myeloma. Molecular Biology Reports. https://doi.org/10.1007/s11033-024-09517-2
Vancouver
Kim H, Oh J, Kim MK, Lee KH, Jeong D. Selenoprotein W engages in overactive osteoclast differentiation in multiple myeloma. Molecular Biology Reports. 2024. doi:10.1007/s11033-024-09517-2
BibTeX
@article{Kim2024,
author = {Kim, Hyunsoo and Oh, Jiin and Kim, Min Kyoung and Lee, Kyung Hee and Jeong, Daewon},
title = {Selenoprotein W engages in overactive osteoclast differentiation in multiple myeloma},
journal = {Molecular Biology Reports},
year = {2024},
doi = {10.1007/s11033-024-09517-2}
}
EUVIMED